RxDoctor Payments Data

Ikenna Onyebueke, MD

Critical Care Medicine · Spartanburg, SCNPI 1700043106

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (41.7%), food and beverage and education — rather than concentrated in one kind of arrangement. 47 manufacturers reported payments, led by Verona Pharma, Inc. at 46.6% of the total. 2025 is the largest year on record at $23,354, more than ten times the $1,936 reported in 2019. Among critical care medicine clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$34,192in general payments, 2019–2025

Across 528 payments — averaging $64.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Verona Pharma, Inc.$16K
  • Intuitive Surgical$6K
  • GSK$2K
  • Veran Medical Technologies, Inc.$1K
  • AstraZeneca$1K
  • Boehringer Ingelheim$864
  • plus $6K from 41 others

What the payments were for

  • Speaking & faculty fees$14,26442%
  • Travel & lodging$4,11412%
  • Food & beverage$11,48834%
  • Education$4,32613%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,192 in reported general payments places this provider in the 90th percentile of 93 critical care medicine providers in South Carolina.

See all critical care medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$236,954
Medicare patients
606
Services billed
3,048

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter816$658,069
Breztri AerosphereBudesonide/Glycopyr/Formoterol208$162,461
Breo ElliptaFluticasone/Vilanterol303$146,014
Stiolto RespimatTiotropium Br/Olodaterol Hcl122$73,222
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr140$69,149
Spiriva RespimatTiotropium Bromide61$41,540
Arnuity ElliptaFluticasone Furoate132$34,449
SymbicortBudesonide/Formoterol Fumarate71$20,505
Incruse ElliptaUmeclidinium Bromide57$20,190
Albuterol Sulfate HfaAlbuterol Sulfate555$18,612
Roflumilast137$14,378
Fluticasone-SalmeterolFluticasone Propion/Salmeterol74$9,968
Advair HfaFluticasone Propion/Salmeterol19$9,626
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate33$5,583
Fluticasone-VilanterolFluticasone/Vilanterol14$4,723

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta$2,056$927,8721,448 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,256$182,967279 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$864$114,762183 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 93 critical care medicine providers in South Carolina.

Other critical care medicine in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →